BioLineRx starts triple combination arm of COMBAT/KEYNOTE-202 study
BioLineRx has commenced the triple combination arm of the Phase IIa COMBAT/KEYNOTE-202 trial of BL-8040 and keytruda (pembrolizumab) for the…
BioLineRx COMBAT/KEYNOTE-202
BioLineRx has commenced the triple combination arm of the Phase IIa COMBAT/KEYNOTE-202 trial of BL-8040 and keytruda (pembrolizumab) for the…